There are three human isoforms, NRAS, HRAS, and KRAS, and KRAS is frequently mutated in colorectal cancers with 30%–40% mutation rates, moreover, KRAS mutations have been shown to be well-associated with poorer outcomes, in terms of shorter survival times, and being more aggressive and drug-resistant [44,45,46]. The gene discussed is KRAS; the disease is colorectal cancer.